Physician profile
Michael James Oler
NPI 1528040938
$498.41
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.22 · 2020: $116 · 2021: $270 · 2022: $38.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $181.53 | 2021-2022 | |
| Lilly USA, LLC | $108.62 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $39.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $33.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $33.87 | 2020 | |
| Amarin Pharma, INC. | $33.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.58 | 2019-2020 | |
| Amgen INC. | $13.67 | 2020 | |
| Abbott Laboratories | $12.92 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.46 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Oler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.